Konstantina Pantazi

Ms. Konstantina Pantazi

Aristotle University of Thessaloniki, Thessaloníki, Kentrikí Makedonía, Greece
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
KPKonstantina Pantazi
Konstantina Pantazi
Eleni KarlaftiEleni Karlafti
Eleni Karlafti
ABAlexandra Bekiaridou
Alexandra Bekiaridou
Matthaios DidagelosMatthaios Didagelos
Matthaios Didagelos
AZAntonios Ziakas
Antonios Ziakas
TDTriantafyllos Didangelos
Triantafyllos Didangelos
This year, 2022, marks the 100th anniversary of the isolation of human insulin and its administration to patients suffering from diabetes mellitus (DM). Insulin exerts many effects on the human body, including the cardiac tissue. The pathways implicated include the PKB/Akt signaling pathway, the Janus kinase, and the mitogen-activated protein kinase pathway and lead to normal cardiac growth, vascular smooth muscle regulation, and cardiac contractility. This review aims to summarize the existing knowledge and provide new insights on insulin pathways of cardiac tissue, along with the role of left ventricular assist devices on insulin regulation and cardiac function.

15 December 2022 in Medicina
Verified
Journal Article
Open access
PDF file
Eleni KarlaftiEleni Karlafti
Eleni Karlafti
Daniel ParamythiotisDaniel Paramythiotis
Daniel Paramythiotis
KPKonstantina Pantazi
Konstantina Pantazi
Vasiliki Epameinondas GeorgakopoulouVasiliki Epameinondas Georgakopoulou
Vasiliki Epameinondas Georgakopoulou
CKChristos Kaiafa
Christos Kaiafa
Christos SavopoulosChristos Savopoulos
Christos Savopoulos
In the last few years, the world has had to face the SARS-CoV-2 infection and its multiple effects. Even though COVID-19 was first considered to be a respiratory disease, it has an extended clinical spectrum with symptoms occurring in many tissues, and it is now identified as a systematic disease. Therefore, various drugs are used during the therapy of hospitalized COVID-19 patients. Studies have shown that many of these drugs could have adverse side-effects, including drug-induced liver injury—also known as DILI—which is the focus of our review. Despite the consistent findings, the pathophysiological mechanism behind DILI in COVID-19 disease is still complex, and there are a few risk factors related to it. However, when it comes to the diagnosis, there are specific algorithms (including the RUCAM algorithm) and biomarkers that can assist in identifying DILI and which we will analyze in our review. As indicated by the title, a variety of drugs are associated with this COVID-19-related complication, including systemic corticosteroids, drugs used for the therapy of uncontrolled cytokine storm, as well as antiviral, anti-inflammatory, and anticoagulant drugs. Bearing in mind that hepatotoxicity is very likely to occur during COVID-19, especially in patients treated with multiple medications, we will also refer to the use of other drugs used for DILI therapy in an effort to control and prevent a severe and long-term outcome.

20 October 2022 in Life
Verified
Journal Article
Open access
PDF file
CKChristos Kaiafa
Christos Kaiafa
Christos SavopoulosChristos Savopoulos
Christos Savopoulos
Eleni KarlaftiEleni Karlafti
Eleni Karlafti
KPKonstantina Pantazi
Konstantina Pantazi
Daniel ParamythiotisDaniel Paramythiotis
Daniel Paramythiotis
TDTriantafyllos Didangelos
Triantafyllos Didangelos
Coronavirus disease is a viral infection that can affect multiple systems and be expressed with many—or no—symptoms. The viral infection begins when the virus binds to the host’s receptor and from that point on, it is transmitted to the rest of the body, where it causes inflammatory reactions. Among other tissues and systems, SARS-CoV-2 impacts the coagulation system, where it triggers the immunothrombotic response. Its effects are rather intense and can lead to many complications. COVID-19-associated coagulopathy is frequently observed in hospitalized patients, especially ICU patients, and can be proven detrimental. It is usually accompanied by other complications, such as sepsis-induced coagulopathy, disseminated intravascular coagulation and venous thromboembolism. Since all these conditions lead to poor prognosis for severely ill patients, thromboprophylaxis and coagulopathy prognosis are just as important as the therapeutic handling of these patients. Since the beginning of the pandemic, many biomarkers have been considered useful when trying to assess the thrombotic risk of hospitalized patients or evaluate the severity of their situation. At the same time, many drugs have already been tested—while others are still being trialed—in order to find the optimal therapy for each urgent situation.